Dana Investment Advisors Inc. decreased its position in Align Technology, Inc. (NASDAQ:ALGN) by 25.1% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 21,106 shares of the medical equipment provider’s stock after selling 7,057 shares during the period. Dana Investment Advisors Inc.’s holdings in Align Technology were worth $3,931,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of ALGN. Vanguard Group Inc. lifted its stake in shares of Align Technology by 16.5% in the 2nd quarter. Vanguard Group Inc. now owns 7,299,099 shares of the medical equipment provider’s stock worth $1,095,740,000 after acquiring an additional 1,034,254 shares during the period. Polen Capital Management LLC lifted its stake in shares of Align Technology by 6.8% in the 2nd quarter. Polen Capital Management LLC now owns 3,362,570 shares of the medical equipment provider’s stock worth $504,789,000 after acquiring an additional 212,773 shares during the period. State Street Corp lifted its stake in shares of Align Technology by 32.2% in the 2nd quarter. State Street Corp now owns 3,143,095 shares of the medical equipment provider’s stock worth $471,823,000 after acquiring an additional 765,189 shares during the period. Bank of New York Mellon Corp lifted its stake in shares of Align Technology by 2.2% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,946,097 shares of the medical equipment provider’s stock worth $362,499,000 after acquiring an additional 42,570 shares during the period. Finally, Renaissance Technologies LLC lifted its stake in shares of Align Technology by 11.3% in the 2nd quarter. Renaissance Technologies LLC now owns 1,587,681 shares of the medical equipment provider’s stock worth $238,343,000 after acquiring an additional 160,881 shares during the period. Hedge funds and other institutional investors own 84.04% of the company’s stock.

Shares of Align Technology, Inc. (ALGN) opened at $235.63 on Thursday. Align Technology, Inc. has a one year low of $88.56 and a one year high of $266.41. The company has a market cap of $18,890.00, a P/E ratio of 69.13, a P/E/G ratio of 2.23 and a beta of 1.43.

Align Technology (NASDAQ:ALGN) last released its earnings results on Thursday, October 26th. The medical equipment provider reported $1.01 EPS for the quarter, beating the consensus estimate of $0.82 by $0.19. Align Technology had a net margin of 19.98% and a return on equity of 25.60%. The business had revenue of $385.30 million during the quarter, compared to analyst estimates of $359.80 million. During the same period in the prior year, the business earned $0.63 earnings per share. The business’s quarterly revenue was up 38.3% on a year-over-year basis. research analysts anticipate that Align Technology, Inc. will post 3.62 EPS for the current fiscal year.

ALGN has been the subject of a number of research analyst reports. Robert W. Baird reaffirmed a “buy” rating and issued a $245.00 price target on shares of Align Technology in a research note on Friday, October 27th. Leerink Swann reaffirmed an “outperform” rating and issued a $250.00 price target on shares of Align Technology in a research note on Friday, October 27th. Credit Suisse Group reaffirmed an “outperform” rating and issued a $276.00 price target (up from $261.00) on shares of Align Technology in a research note on Tuesday, November 28th. Deutsche Bank began coverage on shares of Align Technology in a research note on Friday, December 8th. They set a “hold” rating and a $250.00 target price for the company. Finally, Stifel Nicolaus increased their target price on shares of Align Technology from $205.00 to $225.00 and gave the company a “buy” rating in a research note on Monday, October 23rd. One analyst has rated the stock with a hold rating and eleven have issued a buy rating to the company’s stock. Align Technology has a consensus rating of “Buy” and a consensus price target of $236.75.

In related news, Director Greg J. Santora sold 7,700 shares of the company’s stock in a transaction that occurred on Tuesday, October 31st. The shares were sold at an average price of $238.95, for a total value of $1,839,915.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Joseph Lacob sold 29,724 shares of the company’s stock in a transaction that occurred on Thursday, November 30th. The shares were sold at an average price of $260.91, for a total transaction of $7,755,288.84. The disclosure for this sale can be found here. Over the last three months, insiders have sold 52,849 shares of company stock valued at $13,494,348. Company insiders own 1.60% of the company’s stock.

TRADEMARK VIOLATION WARNING: This article was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this article on another domain, it was illegally copied and reposted in violation of US and international copyright & trademark legislation. The original version of this article can be viewed at https://www.thecerbatgem.com/2017/12/14/align-technology-inc-algn-holdings-reduced-by-dana-investment-advisors-inc.html.

Align Technology Profile

Align Technology, Inc designs, manufactures and markets a system of clear aligner therapy, intra-oral scanners and computer-aided design/computer-aided manufacturing (CAD/CAM) digital services used in dentistry, orthodontics and dental records storage. The Company operates through two segments: Clear Aligner segment and Scanner and Services (Scanner) segment.

Want to see what other hedge funds are holding ALGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Align Technology, Inc. (NASDAQ:ALGN).

Institutional Ownership by Quarter for Align Technology (NASDAQ:ALGN)

Receive News & Stock Ratings for Align Technology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Align Technology and related stocks with our FREE daily email newsletter.